VANCOUVER, British Columbia--(BUSINESS WIRE)--NanoVation Therapeutics, a platform company developing innovative technologies to overcome barriers to nucleic acid delivery, today announced the expansion of its Board of Directors and the close of a funding round led by Convergent Ventures.

不列颠哥伦比亚省温哥华--（商业新闻短讯）--NanoVation Therapeutics是一家开发创新技术以克服核酸输送障碍的平台公司，今天宣布扩大其董事会规模，并结束由融合企业领导的一轮融资。

These two developments preceded NanoVation’s September announcement of an up to US$600 million multi-year partnership with Novo Nordisk to advance the development of novel genetic medicines targeting cardiometabolic and rare diseases.

在这两项发展之前，NanoVation于9月宣布与诺和诺德建立高达6亿美元的多年合作伙伴关系，以推进针对心脏代谢和罕见疾病的新型遗传药物的开发。

The new financing will support the further advancement of NanoVation's lipid nanoparticle (LNP) technology platform for RNA delivery to cells outside of the liver, including the completion of large animal studies. The Board of Directors appointments include Zachariah (Zach) Jonasson, Ph.D., Chief Financial Officer (CFO) and Chief Business Officer (CBO) at Absci and co-founder of Convergent Ventures, and David Main, President and CEO of Notch Therapeutics..

新的融资将支持NanoVation脂质纳米颗粒（LNP）技术平台的进一步发展，用于将RNA递送至肝外细胞，包括完成大型动物研究。董事会的任命包括Absci首席财务官（CFO）和首席商务官（CBO）兼Convergent Ventures联合创始人Zachariah（Zach）Jonasson博士，以及Notch Therapeutics总裁兼首席执行官David Main。。

'This strategic investment and the addition of two industry veterans to our Board mark important milestones in NanoVation's growth trajectory,' said Dominik Witzigmann, Ph.D., co-founder and CEO of NanoVation Therapeutics. 'Zach's deep understanding of emerging technologies and track record of investing in and building successful biotech companies, combined with David's extensive executive leadership experience, help position NanoVation for its next growth phase and new strategic partnerships in cell-specific nucleic acid delivery.'.

NanoVation Therapeutics联合创始人兼首席执行官多米尼克·维齐格曼（DominikWitzigmann）博士说，这项战略投资和董事会两名行业资深人士的加入标志着NanoVation增长轨迹上的重要里程碑扎克对新兴技术的深刻理解以及投资和建立成功的生物技术公司的历史记录，再加上戴维丰富的高管领导经验，有助于NanoVation在下一个增长阶段以及在细胞特异性核酸递送方面建立新的战略伙伴关系。”。

The expansion of NanoVation's Board adds expertise in emerging therapeutic technologies and nucleic acid delivery. Together, Jonasson and Main bring decades of experience building and scaling successful biotechnology companies through strategic collaborations and technology development.

。Jonasson和Main通过战略合作和技术开发，为成功的生物技术公司的建设和规模扩大带来了数十年的经验。

Zachariah Jonasson is currently the CFO and CBO of Absci Corp., a biotechnology company that uses generative AI at scale to create novel therapeutics. At Absci, Jonasson serves on the executive leadership team and is responsible for the company’s financial and business strategy. He is also a co-founder of two venture capital firms, Convergent Ventures and Phoenix Venture Partners (PVP), where he previously led each firm’s investment strategy in the biotechnology sector as a General Managing Partner..

ZachariahJonasson目前是Absci Corp.的首席财务官和首席预算官，Absci Corp.是一家生物技术公司，大规模使用生成人工智能来创造新的治疗方法。在Absci，Jonasson是执行领导团队的成员，负责公司的财务和业务战略。他还是两家风险投资公司Convergent Ventures和Phoenix venture Partners（PVP）的联合创始人，此前他曾作为普通管理合伙人领导每家公司在生物技术领域的投资战略。。

'The new technologies being developed at NanoVation address the existing challenges preventing the efficacious delivery of genetic medicines,' said Jonasson. “I have known this pioneering team for many years and I’m excited to support their mission to usher in a new era of targeted genetic medicines for the benefit of patients.”.

Jonasson说：“NanoVation正在开发的新技术解决了阻碍基因药物有效递送的现有挑战。”。“我认识这个开创性的团队多年了，我很高兴能够支持他们的使命，为患者的利益开创一个靶向遗传药物的新时代。”。

David Main has 30 years of biotechnology leadership experience. He is currently President and CEO of Notch Therapeutics, a company engineering pluripotent stem cells (iPSCs) to create a universal T cell. Previously, he was co-founder, Chairman and CEO of Aquinox Pharmaceuticals and President and CEO of INEX Pharmaceuticals, a company developing lipid-based drug delivery systems for oncology therapeutics.

David Main拥有30年的生物技术领导经验。他目前是Notch Therapeutics的总裁兼首席执行官，Notch Therapeutics是一家设计多能干细胞（iPSC）以创建通用T细胞的公司。此前，他是Aquinox Pharmaceuticals的联合创始人、董事长兼首席执行官，也是INEX Pharmaceuticals的总裁兼首席执行官，INEX Pharmaceuticals是一家为肿瘤治疗开发基于脂质的药物输送系统的公司。

Companies that spun out of INEX include Protiva Biotherapeutics and Tekmira, which was later rebranded as Arbutus Biopharma..

从INEX剥离出来的公司包括Protiva Biotherapeutics和Tekmira，后者后来更名为杨梅生物制药。。

“These strategic developments – the recent partnership announcement, new funding and expansion of the board – significantly enhance NanoVation's position as a leading innovator in nucleic acid delivery,' said Pieter Cullis, Ph.D., current Board Chair and co-founder of NanoVation. 'Welcoming seasoned entrepreneurs like David and Zach strengthens our team, bringing invaluable business acumen that complements our technical expertise.

“这些战略发展——最近宣布的合作伙伴关系、新的资金和董事会的扩大——大大提高了NanoVation作为核酸交付领域领先创新者的地位，”现任董事会主席兼NanoVation联合创始人Pieter Cullis博士说。“欢迎David和Zach等经验丰富的企业家加强了我们的团队，带来了宝贵的商业智慧，补充了我们的技术专长。

Their involvement provides powerful validation of NanoVation’s potential to advance LNP technologies and reach new therapeutic frontiers.'.

他们的参与有力地验证了NanoVation推进LNP技术并达到新的治疗前沿的潜力。”。

About Convergent Ventures

关于融合风险投资

Convergent Ventures is an early-stage venture capital firm focused on outstanding founders whose science-based technologies are game-changing for people and planetary health. The fund actively invests in scientific founders building at the intersection of data and any of biology, chemistry or physics..

Convergent Ventures是一家早期风险投资公司，专注于杰出的创始人，他们的科学技术正在改变人类和全球健康的游戏规则。该基金积极投资于科学创始人在数据与生物学、化学或物理学的交叉点建设。。

About NanoVation Therapeutics

关于NanoVation Therapeutics

NanoVation Therapeutics is a pioneer in the design and creation of lipid nanoparticles (LNPs) for nucleic acid delivery. The company’s LNP technologies aim to overcome the limits of existing approaches to nucleic acid delivery, including the ability to target tissues outside the liver (extrahepatic delivery).

NanoVation Therapeutics是设计和创建用于核酸递送的脂质纳米颗粒（LNPs）的先驱。该公司的LNP技术旨在克服现有核酸递送方法的局限性，包括靶向肝脏外组织的能力（肝外递送）。

NanoVation’s lead technology is its proprietary long-circulating LNP (lcLNP™) platform, which enables functional nucleic acid delivery to extrahepatic cell types and has demonstrated an improved therapeutic index in preclinical studies. NanoVation partners with leading pharmaceutical and biotech companies to enable the development of genetic medicines for previously untreatable diseases.

NanoVation的领先技术是其专有的长循环LNP（lcLNP™）平台，可将功能性核酸递送至肝外细胞类型，并在临床前研究中证明了改善的治疗指数。NanoVation与领先的制药和生物技术公司合作，为以前无法治疗的疾病开发基因药物。

For additional information, please visit nanovationtx.com or follow NanoVation Therapeutics on LinkedIn..

有关更多信息，请访问nanovationtx.com或在LinkedIn上关注NanoVation Therapeutics。。